Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.

Eytan Stein,Jipan Xie,Emilie Duchesneau,Subrata Bhattacharyya,Umakanth Vudumula,Briana Ndife,Gaetano Bonifacio,Annie Guerin,Nanxin Li,George Joseph

PharmacoEconomics（2019）

引用 15|浏览8

暂无评分

摘要

This analysis suggests that midostaurin is a cost-effective treatment for adult patients with newly diagnosed FLT3-mutated AML, from a US third-party payer perspective.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要